We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+12.64%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$10.5B
AUM Growth
+$891M
Cap. Flow
-$92.8M
Cap. Flow %
-0.89%
Top 10 Hldgs %
36.27%
Holding
147
New
14
Increased
53
Reduced
21
Closed
16

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$98.5M
2
SIEN
Sientra, Inc.
SIEN
+$54.3M
3
GILD icon
Gilead Sciences
GILD
+$50.4M
4
MGLN
Magellan Health Services, Inc.
MGLN
+$47.6M
5
VRTX icon
Vertex Pharmaceuticals
VRTX
+$42.9M

Top Sells

Rank Stock Value
1
CFN
CAREFUSION CORPORATION
CFN
+$215M
2
A icon
Agilent Technologies
A
+$79M
3
ARWR icon
Arrowhead Research
ARWR
+$76.5M
4
STJ
St Jude Medical
STJ
+$54.8M
5
QGENF
QIAGEN NV
QGENF
+$38.7M

Sector Composition

Rank Sector Weight
1 Healthcare 85.82%
2 Financials 0.08%
3 Technology 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BIIB icon
1
Biogen
BIIB
$30.4B
$507M 4.85%
1,494,700
+304,600
+26% +$98.5M
BMY icon
2
Bristol-Myers Squibb
BMY
$130B
$454M 4.34%
7,688,700
+396,700
+5% +$22.4M
AMGN icon
3
Amgen
AMGN
$212B
$431M 4.12%
2,708,000
+105,000
+4% +$16.4M
CELG
4
DELISTED
Celgene Corp
CELG
$409M 3.91%
3,657,600
+329,600
+10% +$34.8M
GILD icon
5
Gilead Sciences
GILD
$167B
$401M 3.83%
4,249,500
+487,300
+13% +$50.4M
AGN
6
DELISTED
Allergan plc
AGN
$383M 3.66%
1,488,200
+52,000
+4% +$13M
ABBV icon
7
AbbVie
ABBV
$465B
$349M 3.33%
5,331,100
-146,900
-3% -$9.26M
HCA icon
8
HCA Healthcare
HCA
$92.8B
$316M 3.02%
4,308,000
+95,000
+2% +$6.68M
RLYP
9
DELISTED
RELYPSA INC COM
RLYP
$273M 2.61%
8,857,551
– –
ILMN icon
10
Illumina
ILMN
$29.2B
$273M 2.6%
1,517,945
+137,341
+10% +$24.2M
SHPG
11
DELISTED
Shire pic
SHPG
$249M 2.38%
1,170,000
-49,000
-4% -$10.4M
ISRG icon
12
Intuitive Surgical
ISRG
$130B
$233M 2.22%
3,960,000
+482,400
+14% +$26.9M
ICPT
13
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$232M 2.21%
1,485,000
– –
INCY icon
14
Incyte
INCY
$26B
$230M 2.2%
3,149,300
-105,600
-3% -$6.9M
MDVN
15
DELISTED
MEDIVATION, INC.
MDVN
$226M 2.16%
4,537,800
-8,200
-0.2% -$426K
IPXL
16
DELISTED
Impax Laboratories, Inc.
IPXL
$212M 2.02%
6,678,000
+272,800
+4% +$7.98M
PRGO icon
17
Perrigo
PRGO
$1.43B
$209M 1.99%
1,247,800
+103,100
+9% +$16.1M
VRTX icon
18
Vertex Pharmaceuticals
VRTX
$124B
$206M 1.97%
1,731,200
+381,200
+28% +$42.9M
TMO icon
19
Thermo Fisher Scientific
TMO
$214B
$200M 1.91%
1,595,700
-95,700
-6% -$11.6M
HNT
20
DELISTED
HEALTH NET INC
HNT
$199M 1.9%
3,711,400
+641,000
+21% +$31.6M
COO icon
21
Cooper Companies
COO
$14.1B
$198M 1.89%
4,882,400
+311,600
+7% +$12.5M
ESRX
22
DELISTED
Express Scripts Holding Company
ESRX
$195M 1.87%
2,307,000
+209,000
+10% +$16.3M
MOH icon
23
Molina Healthcare
MOH
$10.5B
$192M 1.83%
3,581,900
+844,000
+31% +$40.9M
IRWD icon
24
Ironwood Pharmaceuticals
IRWD
$626M
$184M 1.76%
14,342,447
– –
A icon
25
Agilent Technologies
A
$39.7B
$166M 1.58%
4,051,000
-1,959,002
-33% -$79M
1
2 3 4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q4 2014 Portfolio in Review

As of Q4 2014, OrbiMed held 147 positions worth $10.5B, up 9.3% from $9.57B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

OrbiMed's Q4 2014 filing shows 14 new, 53 increased, 21 reduced and 16 closed positions. Its largest new stake was Sientra, Inc.: 318,531 shares worth $53.5M. The largest sale was CAREFUSION CORPORATION, an estimated $215M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 84% a quarter earlier, followed by Financials and Technology.

  • OrbiMed's largest Q4 2014 buy was Sientra, Inc.: 318,531 shares worth $53.5M.
  • OrbiMed added most to Biogen in Q4 2014, an estimated $98.5M increase.
  • OrbiMed's biggest Q4 2014 reduction was Agilent Technologies, cutting an estimated $79M.
  • OrbiMed fully exited CAREFUSION CORPORATION in Q4 2014, selling an estimated $215M.
  • OrbiMed's ten largest holdings make up 36% of its $10.5B portfolio in Q4 2014.
  • OrbiMed opened 14 new positions and closed 16 in Q4 2014.
  • OrbiMed's portfolio value rose 9.3% quarter-over-quarter to $10.5B.

Based on OrbiMed's 13F filing for Q4 2014, filed 13 Feb 2015.